BSH 2022 | Unmet needs in CLL: managing immune complications and patients with high-risk disease
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, talks on areas of unmet need in chronic lymphocytic leukemia (CLL). Despite the advent in treatments for CLL, a small number of patients with high-risk features still progress on Bruton’s tyrosine kinase (BTK) inhibitors and venetoclax-based regimens. It is necessary to find alternative treatment options for this patient population. In addition, it is also important to better understand and manage immune complications associated with CLL and CLL therapies, which have a significant impact on morbidity, mortality, and on the patient’s quality of life (QoL). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honoraria: Abbvie; AstraZeneca; Gilead, Janssen; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kirin
